New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2013
09:16 EDTCTICCell Therapeutics has opportunity in MF, says Roth Capital
After attending Cell Therapeutics' Analyst Day, Roth Capital believes the company's pacritinib drug has a material opportunity to become a treatment for myelofibrosis, or MF, given the drug's differentiated profile of having a minimal effect on platelets. The firm maintains a $4 price target and Buy rating on the stock.
News For CTIC From The Last 14 Days
Check below for free stories on CTIC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
09:10 EDTCTICOn The Fly: Pre-market Movers
Subscribe for More Information
05:31 EDTCTICCTI BioPharma to host conference call
Subscribe for More Information
05:18 EDTCTICCTI BioPharma, Servier enter exclusive PIXUVRI license, collaboration agreement
Subscribe for More Information
September 15, 2014
15:06 EDTCTICCTI BioPharma management to meet with Piper Jaffray
Group luncheon to be held in New York on September 16 hosted by Piper Jaffray.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use